Astrid E. Lammers, Ian Adatia, Maria Jesus del Cerro, Gabriel Diaz, Alexandra Heath Freudenthal, Franz Freudenthal, S. Harikrishnan, Dunbar Ivy, Antonio A. Lopes, J ...
In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension. In this event-driven, phase 3, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback